Authors
Maxime Dougados, James Cheng-Chung Wei, Robert Landewé, Joachim Sieper, Xenofon Baraliakos, Filip Van den Bosch, Walter P Maksymowych, Joerg Ermann, Jessica A Walsh, Tetsuya Tomita, Atul Deodhar, Désirée Van Der Heijde, Xiaoqi Li, Fangyi Zhao, Clinton C Bertram, Gaia Gallo, Hilde Carlier, Lianne S Gensler
Publication date
2020/2/1
Journal
Annals of the rheumatic diseases
Volume
79
Issue
2
Pages
176-185
Publisher
BMJ Publishing Group Ltd
Description
Objectives
To investigate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of patients with active radiographic axial spondyloarthritis (r-axSpA) who were biological disease-modifying antirheumatic drug (bDMARD)-naive (COAST-V) or tumour necrosis factor inhibitor (TNFi)-experienced (COAST-W).
Methods
Adults with active r-axSpA were randomised 1:1:1:1 (n=341) to 80 mg ixekizumab every 2 (IXE Q2W) or 4 weeks (IXE Q4W), placebo (PBO) or 40 mg adalimumab Q2W (ADA) in COAST-V and 1:1:1 (n=316) to IXE Q2W, IXE Q4W or PBO in COAST-W. At week 16, patients receiving ixekizumab continued their assigned treatment; patients receiving PBO or ADA were rerandomised 1:1 to IXE Q2W or IXE Q4W (PBO/IXE, ADA/IXE) through week 52.
Results
In COAST-V, Assessment of SpondyloArthritis international Society 40 (ASAS40) responses rates (intent-to-treat population, non …
Scholar articles
M Dougados, JCC Wei, R Landewé, J Sieper… - Annals of the rheumatic diseases, 2020